ACCESS Newswire

CGFNS International

Share
As Health Systems Struggle With Nursing Shortages, CGFNS International Sees a Sharp Rise in Nurses Seeking to Migrate to the U.S.

Report Shows Visa Certifications Hitting a New High in 2023 But a Decline is Likely With U.S. Immigration Limits

PHILADELPHIA, PA / ACCESSWIRE / December 6, 2023 / In a report published today, CGFNS International revealed that in 2023, it issued its highest-ever number of occupational visa certifications to nurses and other skilled health workers seeking to migrate to the U.S., where health systems confront a staffing crisis.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
CGFNS 2023 Nurse Migration Report

The company, a non-profit that verifies credentials for immigration authorities and state licensing boards, said it issued nearly 27,000 of its VisaScreen® certificates during the government fiscal year that ended in October. That is more than twice the number of certificates CGFNS issued the previous year.

The increase continues a six-year upward trend, during which the annual number of VisaScreen® certificates has quadrupled. Over this time, U.S. health systems have increasingly scrambled to fill staff vacancies amid a longstanding nursing shortage that was aggravated by pandemic-era challenges and is projected to worsen through the end of the decade.

In the report, CGFNS stated that higher levels of nurse immigration in recent years are likely to have peaked, even as the nursing shortage widens. This is because, barring intervention, U.S. visa availability is declining to pre-pandemic levels.

Download the 2023 Nurse Migration Report: Navigating Nursing Shortages and Immigration Barriers.

Data in the report were derived from applicant information submitted to the VisaScreen® Service and the CGFNS Credentials Evaluation Service, two leading pathways through which foreign-educated nurses and other healthcare professionals can migrate to and work in the U.S.

Other key findings in the report:

  • The Philippines continues to be by far the largest source of immigrant nurses for the U.S., accounting for more than 60% of the total VisaScreen® certificates issued by CGFNS.
  • In 2023, the vast majority (85%) of certificates were issued to registered nurses (RNs), with another 14% issued to clinical laboratory scientists.
  • More than three-quarters (78%) of those applying for certificates were seeking permanent green cards, up from 64% in 2018 and up nine percentage points in just the past year, showing a strong trend toward permanent migration among nurses.

"Recruitment of nurses from outside the U.S. by using best practices has been critical to helping U.S. health systems cope with extraordinary staffing challenges and to ensure patient safety. With many thousands of qualified foreign-trained nurses willing and waiting to migrate to meet this present need, now is not the time to further restrict their numbers, especially when nurses want to come to the U.S. to advance their careers," said Peter Preziosi, President and CEO of CGFNS.

Contact Information

David St. John
dstjohn@cgfns.org

SOURCE: CGFNS International

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/813769/as-health-systems-struggle-with-nursing-shortages-cgfns-international-sees-a-sharp-rise-in-nurses-seeking-to-migrate-to-the-us

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release

Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e

Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release

Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress

Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release

BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut

RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye